EP1082959A1 — NK1 Antagonists for the treatment of depression
Assigned to Glaxo Group Ltd · Expires 2001-03-14 · 25y expired
What this patent protects
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of depression. Also described are novel tachykinin antagonists, processes for their preparation, pharmaceutical compositions co…
USPTO Abstract
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of depression. Also described are novel tachykinin antagonists, processes for their preparation, pharmaceutical compositions containing them and their medical use. wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R 1 is selected from halogen atoms and C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, and S(0) n C 1-4 alkyl groups; R 2 and R 3 , which may be the same or different, each independently are selected from hydrogen and halogen atoms and C 1-4 alkyl, C 1- 4 alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.